Nicholas Hornstein, Assistant Professor of Medical Oncology at Northwell Health, shared a post on X:
“HER2 blockade in resectable gastric cancer without benefit.
Addition of Herceptin +/- pertuzumab to FLOT did not have significant benefit for resectable gastric patients.
EORTC-1203
Notable response rate improvement adding trastuzumab to Ctx (23 vs 37 %)
Negative study, but more to come for anti-her2 therapies in gastric.”
More posts featuring Nicholas Hornstein.